Abstract
Heparin bonding of an extracorporeal circuit for cardiopulmonary bypass (CPB) improves the biocompatibility and reduces the activation of complements. We evaluated biocompatibility of heparin-bonded Carmeda MAXIMA membrane oxygenator and circuit in clinical cases undergoing CABG or valve replacement. In group NC (n=10), whole CPB circuit was non-heparin bonded. In group PC (n=10), only oxygenator of CPB circuit was heparin-bonded. In group FC (n-B), whole CPB circuit including oxygenator was heparin boded. The reduction of fibrinogen in group PC and FC was less than group NC. C3a and hemolysis were less in group PC and FC than group NC. However there was not significant differences between group PC and FC. We conclude that heparin-bonded Carmeda oxygenator improves biocompatibility as well as fully bonded CPB circuit in clinical use.
